Table 1.
Design of the experimental study groups.
| Day | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 7 (i.p.) | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 22 (s.c.) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | |||||||||||||||||||||||||
| N-C | saline by gavage | CB | saline by gavage | SS | |||||||||||||||||||||
| AMI-C | CB | ISO | |||||||||||||||||||||||
| DM-C | STZ | SS | |||||||||||||||||||||||
| DM-AMI-C | STZ | ISO | |||||||||||||||||||||||
| S-DM-CUS-AMI | STZ | CUS by gavage | ISO | ||||||||||||||||||||||
| CUS-DM-CUS-AMI | CUS by gavage | STZ | ISO | ||||||||||||||||||||||
| S-DM-CUN-AMI | saline by gavage | STZ | CUN by gavage | ISO | |||||||||||||||||||||
| CUN-DM-CUN-AMI | CUN by gavage | STZ | ISO | ||||||||||||||||||||||
Notes: N, normal; C, control; AMI, acute myocardial infarction; DM, diabetes mellitus; SS, saline solution (0.09%); CB, citrate buffer; CUS, curcumin solution (200 mg/kg bw); CUN, curcumin nanoparticle solution (200mg/kg bw); STZ, streptozotocin in a dose of 65 mg/kg bw; ISO, isoproterenol in a dose of 45 mg/kg bw; i.p., intraperitoneal; s.c., subcutaneous.